Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

Blood. 2014 Dec 11;124(25):3829-30. doi: 10.1182/blood-2014-10-604272.

Authors

Julie R McMullen¹, Esther J H Boey¹, Jenny Y Y Ooi¹, John F Seymour², Michael J Keating³, Constantine S Tam²

Affiliations

¹ Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
² Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
³ Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 25498454
DOI: 10.1182/blood-2014-10-604272

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Animals
Animals, Newborn
Atrial Fibrillation / chemically induced
Atrial Fibrillation / metabolism*
Gene Expression Regulation, Enzymologic / drug effects
Humans
Infant, Newborn
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Lymphoma, Mantle-Cell / drug therapy
Myocytes, Cardiac / drug effects
Myocytes, Cardiac / metabolism
Phosphatidylinositol 3-Kinases / metabolism*
Piperidines
Protein-Tyrosine Kinases / antagonists & inhibitors
Protein-Tyrosine Kinases / genetics
Protein-Tyrosine Kinases / metabolism
Proto-Oncogene Proteins c-akt / metabolism*
Pyrazoles / adverse effects*
Pyrazoles / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
Rats
Risk Factors
Signal Transduction / drug effects*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Proto-Oncogene Proteins c-akt
Adenine